- Time of issue:2020-09-21 10:29:25
Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. Over the years, the company has developed a diverse product pipeline with androgen receptors (AR) related diseases at the core. Our products cover multiple global high incidence cancers and other disease areas that have huge unmet medical needs, including prostate cancer, breast cancer, liver cancer and hair loss, etc. Kintor has developed a visionary product pipeline including small molecule innovative drugs, biologics and the combination therapies. The diversified product pipeline includes 5 products that are undergoing clinical research, including androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR inhibitors and Hedgehog/SMO inhibitors. The company also has diverse ongoing preclinical programs, such as PD-L1/TGF-β dual-targeting antibody, AR - Degrader and c - Myc inhibitors etc. We are actively seeking partnerships for China and worldwide, welcome to contact us!
Tel：+86 512 6263 9916，+86 512 6263 9920
Scan the QR code to read on your phone